Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Semaglutide vs Tirzepatide: Study, Side-Effect & Evidence Comparison
An educational, source-based comparison of Semaglutide and Tirzepatide — how each peptide works, what it's researched for, and what to know before going deeper.
A long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central GLP-1 receptors.
- Type 2 diabetes (Ozempic, Rybelsus)
- Obesity / chronic weight management (Wegovy)
- Cardiovascular risk reduction (SELECT trial)
- • FDA-approved with established safety profile but real side effects (GI, pancreatitis risk, gallbladder events).
- • Requires physician oversight and prescription.
- • Compounded versions vary in quality.
A dual agonist of the GLP-1 and GIP receptors. The combined incretin action improves glucose control and produces greater weight loss than GLP-1 monotherapy in head-to-head trials.
- Type 2 diabetes (Mounjaro)
- Chronic weight management (Zepbound)
- Sleep apnea in obesity (recent approval)
- • FDA-approved; requires prescription and physician oversight.
- • GI side effects are dose-limiting.
- • Compounded versions are not FDA-evaluated.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Semaglutide | Semaglutide for weight loss in adults with overweight or obesity (STEP 1) | New England Journal of Medicine | 2021 | Mean ~15% weight loss at 68 weeks versus placebo. |
| Semaglutide | Cardiovascular outcomes with semaglutide (SELECT) | New England Journal of Medicine | 2023 | Reduced MACE in adults with CVD and overweight/obesity. |
| Tirzepatide | Tirzepatide once weekly for weight management (SURMOUNT-1) | New England Journal of Medicine | 2022 | Up to ~21% mean weight loss at 72 weeks at the highest dose. |
Side-effect & safety grid
- FDA-approved with established safety profile but real side effects (GI, pancreatitis risk, gallbladder events).
- Requires physician oversight and prescription.
- Compounded versions vary in quality.
- FDA-approved; requires prescription and physician oversight.
- GI side effects are dose-limiting.
- Compounded versions are not FDA-evaluated.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Semaglutide vs Tirzepatide — Key differences
- Class: Semaglutide is classified as Metabolic · Incretin, while Tirzepatide is Metabolic · Incretin.
- Primary research focus: Semaglutide — type 2 diabetes (ozempic, rybelsus); Tirzepatide — type 2 diabetes (mounjaro).
- Tag: Weight loss vs Weight loss.